Psychedelic-assisted therapy – A New Vision for Mental Health

Australia legalises psychedelics for mental health

Author: Editorial 3rd July 2023 0 Comments

Tiffany Wertheimer reports for the BBC: “Australia has become the first country in the world to legalise the use of psychedelics to treat some mental health conditions. Approved psychiatrists can now prescribe MDMA to those suffering post-traumatic stress disorder and magic…
Read more

collaborative practice

Australia, BBC, depression, magic mushrooms, MDMA, New Approaches, psilocybin, Psychedelic-assisted therapy, PTSD, Therapeutic Goods Administration, Tiffany Wertheimer

Psychedelic drug trip improves symptoms of depression for six months, breakthrough study finds

Author: Editorial 6th April 2023 0 Comments

Nina Massey reports for The Independent: “A psychedelic drug that gives trips lasting half an hour improves the symptoms of moderate to severe depression for up to six months, early trial results suggest. Biotechnology company Small Pharma announced the results of…
Read more

collaborative practice

depression, Dimethyltryptamine, Nina Massey, Psychedelic-assisted therapy, Robin Carhart-Harris, Small Pharma, The Independent

Pattern Breaking: A Complex Systems Approach to Psychedelic Medicine

Author: Editorial 22nd March 2023 0 Comments

This paper (by Inês Hipólito‬, Jonas Mago, Fernando Rosas, and Robin Carhart-Harris) has been published by PsyArXiv Preprints. The abstract says: “Recent research has demonstrated the potential of psychedelic therapy for mental health care. However, the psychological experience underlying its therapeutic…
Read more

collaborative practice

complex systems, complexity science, complexity-based practice, entropic brain hypothesis, PsyArXiv Preprints, Psychedelic-assisted therapy, RElaxed Beliefs Under pSychedelics (REBUS)

My Mind Medicine Australia Psychedelic Lecture Tour

Author: Editorial 8th March 2023 0 Comments

This article by Prof. David Nutt has been published by Drug Science. It begins: “I have just come back from a 3-week lecture tour of South-Eastern Australia supporting the cause of the charity Mind Medicine Australia (MMA) They have been raising money for psychedelic…
Read more

collaborative practice

Australia, David Nutt, Drug Science, MDMA, Mind Medicine Australia, psilocybin, Psychedelic-assisted therapy, Randomised Control Trials (RCTs), Real World Evidence, Research

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

Author: Editorial 3rd January 2023 0 Comments

This research paper has been published in eClinicalMedicine. The summary says: “Background Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been shown to markedly decrease symptom severity in an open-label setting or when compared to…
Read more

collaborative practice

depression, eClinicalMedicine, efficacy, magic mushrooms, Placebo-controlled, psilocybin, Psychedelic-assisted therapy, Randomised Control Trials (RCTs), RCT, Research

Depression is more than low mood – it’s a change of consciousness

Author: Editorial 9th December 2021 0 Comments

As published on the Psyche website, this article has been co-authored by by Cecily Whiteley and Prof. Jonathan Birch. It begins: “You’ve lost a habitable Earth. You’ve lost the invitation to live that the Universe extends to us at every moment….
Read more

Key posts

Cecily Whiteley, consciousness, depression, global state of consciousness, Jonathan Birch, neuroscience, New Approaches, Psyche, Psychedelic-assisted therapy

Psychedelic therapy could ‘reset’ depressed brain

Author: Editorial 18th March 2021 0 Comments

Rachel Schraer reports for the BBC: “A powerful hallucinogenic drug known for its part in shamanic rituals is being trialled as a potential cure for depression for the first time. Participants will be given the drug DMT, followed by talking therapy….
Read more

collaborative practice

ayahuasca, BBC, Carol Routledge, depression, DMT, psychedelic drugs, Psychedelic-assisted therapy, Rachel Schraer, Research, Small Pharma